Veracyte Announces Second Quarter 2024 Financial Results

Rhea-AI Summary

Veracyte reported a 27% increase in total revenue for Q2 2024, reaching $114.4 million, driven by robust performance of Decipher and Afirma tests.

Testing revenue grew by 31%, while test volume increased by 23% to 39,023. Net income rose to $5.7 million, up 168%, and adjusted EBITDA was $24.0 million, representing 21% of revenue.

Decipher Prostate test volumes surged to nearly 19,900, aided by updated NCCN guidelines. Afirma test volume was approximately 15,700, bolstered by new Medicare coverage.

Total gross margin improved to 68%, and non-GAAP gross margin to 71%. Despite a 3% decrease in product revenue and a 22% decline in biopharmaceutical revenue, operational cash generation was strong at $26.7 million, ending the quarter with $235.9 million in cash and equivalents.

The company has updated its 2024 financial outlook, raising full-year revenue guidance to $432-$438 million and expecting year-end cash reserves of $260-$270 million.

Positive

• Total revenue increased by 27% to $114.4 million.
• Testing revenue grew by 31% to $107.0 million.
• Net income increased by 168% to $5.7 million.
• Adjusted EBITDA improved by 118% to $24.0 million.
• Record Decipher Prostate test volume close to 19,900 tests.
• Afirma test volume reached approximately 15,700 tests.
• Gross margin increased to 68%, and non-GAAP gross margin to 71%.
• Operational cash generation of $26.7 million, ending the quarter with $235.9 million in cash and equivalents.
• Raised full-year 2024 revenue guidance to $432-$438 million.

Negative

• Product revenue decreased by 3% to $3.9 million.
• Biopharmaceutical and other revenue declined by 22% to $3.6 million.

Financial Analyst

Veracyte's Q2 2024 results demonstrate strong financial performance and market penetration. Total revenue grew 27% to $114.4 million, primarily driven by a 31% increase in testing revenue. The company's flagship tests, Decipher Prostate and Afirma, showed robust growth, indicating market share gains. Notably, Decipher Prostate achieved record volume following updated NCCN guidelines, while Afirma benefited from expanded Medicare coverage.

Profitability metrics improved significantly, with net income reaching $5.7 million and adjusted EBITDA at $24.0 million (21% of revenue). The company's strong cash position ($235.9 million) and positive cash flow ($26.7 million generated in Q2) provide financial flexibility for future growth initiatives. The raised full-year guidance suggests continued momentum, projecting 20-21% total revenue growth for 2024.

Market Research Analyst

Veracyte's Q2 results reflect strong market dynamics in precision medicine diagnostics. The record volumes for Decipher Prostate (19,900 tests) and Afirma (15,700 tests) indicate growing physician adoption and expanding market opportunities. The updated NCCN guidelines favoring Decipher Prostate and expanded Medicare coverage for Afirma are significant catalysts for future growth.

The company's focus on evidence expansion, demonstrated by three published Decipher Prostate studies, enhances its competitive position. The real-world analysis linking Decipher data to the SEER database underscores the test's clinical utility and the strength of Veracyte's diagnostic platform. This commitment to clinical validation could drive further market penetration and potentially open new revenue streams in the biopharmaceutical sector, despite the 22% decrease in biopharma revenue this quarter.

Medical Research Analyst

Veracyte's Q2 results highlight the growing importance of precision diagnostics in oncology and endocrinology. The strong performance of Decipher Prostate, particularly following its highest-level rating among gene expression tests in NCCN guidelines, demonstrates the increasing reliance on molecular diagnostics for treatment decisions in prostate cancer. This trend is likely to continue as more oncologists recognize the value of personalized risk stratification.

The expanded Medicare coverage for Afirma in Bethesda V thyroid nodules is a significant development, potentially improving patient care by reducing unnecessary surgeries. The company's focus on evidence generation, including real-world studies linking diagnostic data to clinical outcomes, is important for long-term success in the competitive diagnostics market. This approach not only validates existing tests but also paves the way for future test development and market expansion.

Grew total revenue to $114.4 million, an increase of 27%

Grew testing revenue by 31%

Conference call and webcast today at 4:30 p.m. ET

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Veracyte, Inc. (Nasdaq: VCYT) today announced financial results for the second quarter ended June 30, 2024.

“Our exceptional second quarter results are a testament to the strength and robustness of Decipher and Afirma,” said Marc Stapley, Veracyte’s chief executive officer. “With both tests clearly gaining share in their respective markets and plenty of headroom for durable future expansion, our confidence in their long-term prospects continues to grow. Meanwhile, our positive cash generation and class-leading profitability profile are fueling a portfolio of tests that are poised to drive meaningful advances in precision medicine.”

Key Business Highlights

• Increased second quarter total revenue by 27%, to $114.4 million, compared to the second quarter of 2023.
• Grew total test volume to 39,023, an increase of 23% compared to the second quarter of 2023.
• Increased second quarter net income to $5.7 million and delivered adjusted EBITDA of $24.0 million, or 21% of revenue.
• Achieved record Decipher Prostate test volume of close to 19,900 tests, driven by recently updated NCCN* prostate cancer guidelines, in which the Decipher Prostate test received the highest-level rating among gene expression tests.
• Delivered record Afirma test volume of approximately 15,700 and received Medicare coverage for Afirma testing of patients with thyroid nodules classified as “Bethesda V,” giving more patients annually access to the test.
• Reinforced Veracyte’s commitment to evidence expansion with three published Decipher Prostate test studies, including a real-world, population-based analysis of Decipher data linked to the National Cancer Institute’s SEER database demonstrating the test’s clinical utility and underscoring the power of the Veracyte Diagnostics Platform.
• Generated $26.7 million of cash during the second quarter to end the quarter with $235.9 million of cash and cash equivalents.

* National Comprehensive Cancer Network. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

A reconciliation of GAAP to non-GAAP financial measures has been provided in the tables included in this press release. An explanation of these measures is also included below under the heading "Note Regarding Use of Non-GAAP Financial Measures."

Second Quarter 2024 Financial Results

Total revenue for the second quarter of 2024 was $114.4 million, an increase of 27% compared to $90.3 million reported in the second quarter of 2023. Testing revenue was $107.0 million, an increase of 31% compared to $81.7 million in the second quarter of 2023, driven by the strong performance of our Decipher Prostate and Afirma tests. Product revenue was $3.9 million, a decrease of 3% compared to $4.0 million in the second quarter of 2023. Biopharmaceutical and other revenue was $3.6 million, a decrease of 22% compared to $4.6 million in the second quarter of 2023.

Total gross margin for the second quarter of 2024 was 68%, compared to 62% in the second quarter of 2023. Non-GAAP gross margin, which excludes the amortization of acquired intangible assets, stock-based compensation, other acquisition related expenses, and certain other adjustments was 71%, compared to 68% in the second quarter of 2023.

Operating expenses were $73.3 million for the second quarter of 2024. Non-GAAP operating expenses, which excludes amortization of acquired intangible assets, stock-based compensation, other acquisition related expenses, and other restructuring costs, grew 14% to $59.0 million compared to $51.7 million in the second quarter of 2023.

Net income for the second quarter of 2024 was $5.7 million, an improvement of 168% compared to the second quarter of 2023. Basic and diluted net earnings per common share was $0.07, an improvement of $0.19 compared to the second quarter of 2023. Non-GAAP diluted net earnings per common share was $0.30, an improvement of $0.18 compared to the second quarter of 2023. Net cash provided by operating activities in the first six months of 2024 was $20.6 million, an improvement of $6.1 million compared to the same period in 2023.

Adjusted EBITDA for the second quarter of 2024 was $24.0 million, an improvement of 118% compared to the second quarter of 2023, representing 21% of revenue compared to 12% of revenue respectively.

A reconciliation of GAAP to non-GAAP financial measures has been provided in the tables included in this press release. An explanation of these measures is also included below under the heading "Note Regarding Use of Non-GAAP Financial Measures."

2024 Financial Outlook

The company is raising full-year 2024 total revenue guidance to $432 million to $438 million, representing year-over-year growth of 20% to 21% and testing revenue growth of approximately 25%. This guidance range represents an increase compared to prior guidance of $402 million to $410 million. In addition, the company now expects cash, cash equivalents and short-term investments at the end of the year to be $260 million to $270 million compared to prior guidance of $236 million to $240 million.

Conference Call and Webcast Details

Veracyte will host a conference call and webcast today at 4:30 p.m. Eastern Time to discuss the company's financial results and provide a general business update. The conference call will be webcast live from the company’s website and will be available via the following link: https://edge.media-server.com/mmc/p/p5tuszv4. The webcast should be accessed 10 minutes prior to the conference call start time. A replay of the webcast will be available for one year following the conclusion of the live broadcast and will be accessible on the company’s website at https://investor.veracyte.com/events-presentations.

The conference call dial-in can be accessed by registering at the following link: https://register.vevent.com/register/BIbb7f6b70b4ce4820b6391059390d6139

About Veracyte

Veracyte (Nasdaq: VCYT) is a global diagnostics company whose vision is to transform cancer care for patients all over the world. We empower clinicians with the high-value insights they need to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. Our Veracyte Diagnostics Platform delivers high-performing cancer tests that are fueled by broad genomic and clinical data, deep bioinformatic and AI capabilities, and a powerful evidence-generation engine, which ultimately drives durable reimbursement and guideline inclusion for our tests, along with new insights to support continued innovation and pipeline development. For more information, please visit www.veracyte.com or follow us on LinkedIn or X (Twitter).

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements, including, but not limited to our statements related to our plans, objectives, and expectations (financial and otherwise), including with respect to 2024 financial and operating results; and our intentions with respect to our tests and products, for use in diagnosing and treating diseases, in and outside of the United States. Forward-looking statements can be identified by words such as: “appears,” “anticipate,” “intend,” “plan,” “expect,” “believe,” “should,” “may,” “will,” “enable,” “positioned,” “offers,” “designed” and similar references to future periods. Actual results may differ materially from those projected or suggested in any forward-looking statements. These statements involve risks and uncertainties, which could cause actual results to differ materially from our predictions, and include, but are not limited to: our ability to launch, commercialize and receive reimbursement for our products; our ability to execute on our business strategies relating to the C2i Genomics acquisition, integration of the business and the realization of expected benefits and synergies; our ability to demonstrate the validity and utility of our genomic tests and biopharma and other offerings; our ability to continue executing on our business plan; our ability to continue to scale our global operations and enhance our internal control environment; the impact of the war in Ukraine and other regional conflicts on European economies and our facilities in France; the impact of foreign currency fluctuations, increasing interest rates, inflation, the U.S. election and turmoil in the global banking and finance system; the ongoing conflict in the Middle East and the performance and utility of our tests in the clinical environment. Additional factors that may impact these forward-looking statements can be found under the caption “Risk Factors” in our Annual Report on Form 10-K filed on February 29, 2024, and our Quarterly Report on Form 10-Q filed for the three months ended June 30, 2024, to be filed August 7, 2024, as well as in other documents that we may file from time to time with the Securities and Exchange Commission. Copies of these documents, when available, may be found in the Investors section of our website at investor.veracyte.com. These forward-looking statements speak only as of the date hereof and, except as required by law, we specifically disclaim any obligation to update these forward-looking statements or reasons why actual results might differ, whether as a result of new information, future events or otherwise.

Veracyte, the Veracyte logo, Decipher, C2i Genomics, and Afirma are registered trademarks of Veracyte, Inc., and its subsidiaries in the U.S. and selected countries.

Note Regarding Use of Non-GAAP Financial Measures

In addition to the financial measures prepared in accordance with generally accepted accounting principles (GAAP), this press release and the accompanying tables contain, and reference certain non‐GAAP results including non-GAAP gross margin, non-GAAP operating expenses, adjusted EBITDA and non-GAAP earnings per share (EPS). These non-GAAP financial measures are not meant to be considered superior to or a substitute for financial measures calculated in accordance with GAAP, and investors are cautioned that there are material limitations associated with the use of non-GAAP financial measures as an analytical tool.

We use non-GAAP financial measures to internally evaluate and analyze financial results. We believe these non-GAAP financial measures provide investors with useful supplemental information about the financial performance of our business, enable comparison of financial results between periods where certain items may vary independent of business performance, and enable comparison of our financial results with other public companies, many of which present similar non-GAAP financial measures. However, the non-GAAP financial measures we present may be different from those used by other companies.

We exclude amortization of acquired intangible assets, acquisition-related expenses relating to our acquisitions of Decipher Biosciences, HalioDx and C2i Genomics, impairment charges associated with the nCounter license and other biopharmaceutical services related to HalioDx intangible assets, all stock-based compensation and certain costs related to restructuring from certain of our non-GAAP financial measures. Beginning in the second quarter of 2024, we changed our non-GAAP policy to exclude all stock-based compensation to align with our peers and we have also excluded all stock-based compensation from our prior period non-GAAP financial measures. Management has excluded the effects of these items in non-GAAP financial measures to help investors gain a better understanding of the core operating results and future prospects of the company, consistent with how management measures and forecasts the company's performance, especially when comparing such results to previous periods or forecasts. The company encourages investors to carefully consider its results under GAAP, as well as its supplemental non‐GAAP information and the reconciliation between these presentations, to more fully understand its business.

VERACYTE, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
(In thousands, except share and per share amounts)
	Three Months Ended June 30,							Six Months Ended June 30,
	2024			2023				2024				2023
Revenue:
Testing revenue	$	106,970		$	81,749			$	197,273			$	154,145
Product revenue		3,906			4,011				7,443				7,903
Biopharmaceutical and other revenue		3,552			4,562				6,556				10,696
Total revenue		114,428			90,322				211,272				172,744
Cost of revenue (1):
Cost of testing revenue		27,920			23,333				53,899				42,981
Cost of product revenue		1,874			2,315				4,518				4,477
Cost of biopharmaceutical and other revenue		3,812			4,040				6,650				8,459
Intangible asset amortization - cost of revenue		2,909			4,814				5,824				9,618
Total cost of revenue		36,515			34,502				70,891				65,535
Gross profit		77,913			55,820				140,381				107,209
Operating expenses (1):
Research and development		16,465			12,541				32,430				25,310
Selling and marketing		24,216			25,756				47,998				51,886
General and administrative		31,745			25,047				57,955				46,100
Impairment of long-lived assets		—			—				429				1,410
Intangible asset amortization - operating expenses		881			527				1,619				1,052
Total operating expenses		73,307			63,871				140,431				125,758
Income (loss) from operations		4,606			(8,051	)			(50	)			(18,549	)
Other income (loss), net		2,755			(226	)			5,503				2,181
Income (loss) before income taxes		7,361			(8,277	)			5,453				(16,368	)
Income tax provision		1,627			125				1,583				125
Net Income (loss)	$	5,734		$	(8,402	)		$	3,870			$	(16,493	)
Earnings (loss) per share:
Basic	$	0.07		$	(0.12	)		$	0.05			$	(0.23	)
Diluted	$	0.07		$	(0.12	)		$	0.05			$	(0.23	)
Shares used to compute earnings (loss) per common share:
Basic		76,538,325			72,478,662				75,649,057				72,327,897
Diluted		77,163,149			72,478,662				76,600,079				72,327,897

1. Cost of revenue, research and development, sales and marketing and general and administrative expenses include the following stock-based compensation related expenses:

	Three Months Ended June 30,						Six Months Ended June 30,
	2024			2023			2024			2023
Cost of revenue	$	604		$	497		$	1,091		$	884
Research and development		1,895			1,439			3,658			2,696
Selling and marketing		2,142			2,494			3,235			4,606
General and administrative		5,213			6,019			9,889			10,364
Total stock-based compensation expense	$	9,854		$	10,449		$	17,873		$	18,550

VERACYTE, INC.
CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME (LOSS)
(Unaudited)
(In thousands)
	Three Months Ended June 30,								Six Months Ended June 30,
	2024				2023				2024				2023
Net income (loss)	$	5,734			$	(8,402	)		$	3,870			$	(16,493	)
Other comprehensive income (loss):
Change in currency translation adjustments		(1,703	)			(917	)			(6,592	)			3,563
Net comprehensive income (loss)	$	4,031			$	(9,319	)		$	(2,722	)		$	(12,930	)

VERACYTE, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands)
	June 30,			December 31,
	2024			2023
	(Unaudited)			(See Note 1)
Assets
Current assets:
Cash and cash equivalents	$	235,915		$	216,454
Accounts receivable		50,304			40,378
Supplies and inventory		19,258			16,128
Prepaid expenses and other current assets		15,629			12,661
Total current assets		321,106			285,621
Property, plant and equipment, net		22,291			20,584
Right-of-use assets, operating leases		18,116			10,277
Intangible assets, net		112,532			88,593
Goodwill		752,107			702,984
Restricted cash		1,088			876
Other assets		7,087			5,971
Total assets	$	1,234,327		$	1,114,906
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable	$	12,084		$	12,943
Accrued liabilities		43,455			38,427
Current portion of deferred revenue		2,195			2,008
Current portion of acquisition-related contingent consideration		7,348			2,657
Current portion of operating lease liabilities		7,185			5,105
Current portion of other liabilities		72			101
Total current liabilities		72,339			61,241
Deferred tax liabilities		1,483			734
Acquisition-related contingent consideration, net of current portion		13,889			518
Operating lease liabilities, net of current portion		13,553			7,525
Other liabilities		540			786
Total liabilities		101,804			70,804
Total stockholders’ equity		1,132,523			1,044,102
Total liabilities and stockholders’ equity	$	1,234,327		$	1,114,906

1. The condensed consolidated balance sheet at December 31, 2023 has been derived from the audited financial statements at that date included in the Company's Form 10-K filed with the Securities and Exchange Commission dated February 29, 2024.

VERACYTE, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
(In thousands)
	Six Months Ended June 30,
	2024				2023
Operating activities
Net income (loss)	$	3,870			$	(16,493	)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization		11,328				13,529
Loss on disposal of property, plant and equipment		68				136
Stock-based compensation		17,873				18,366
Deferred income taxes		23				125
Noncash lease expense		2,287				1,977
Revaluation of acquisition-related contingent consideration		863				(344	)
Effect of foreign currency on operations		896				(167	)
Impairment loss		429				1,410
Changes in operating assets and liabilities:
Accounts receivable		(10,086	)			1,789
Supplies and inventory		(3,266	)			2,782
Prepaid expenses and other current assets		(2,183	)			(2,530	)
Other assets		(1,213	)			(1,048	)
Operating lease liabilities		(2,446	)			(2,091	)
Accounts payable		(1,706	)			792
Accrued liabilities and deferred revenue		3,872				(3,734	)
Net cash provided by operating activities		20,609				14,499
Investing activities
Acquisition of C2i, net of cash acquired		5,012				—
Purchase of short-term investments		—				(19,700	)
Proceeds from sale of short-term investments		—				39,773
Proceeds from maturity of short-term investments		—				5,000
Purchases of property, plant and equipment		(4,904	)			(4,662	)
Net cash provided by investing activities		108				20,411
Financing activities
Payment of taxes on vested restricted stock units		(5,135	)			(3,168	)
Proceeds from the exercise of common stock options and employee stock purchases		4,260				5,250
Net cash (used in) provided by financing activities		(875	)			2,082
Increase in cash, cash equivalents and restricted cash		19,842				36,992
Effect of foreign currency on cash, cash equivalents and restricted cash		(169	)			43
Net increase in cash, cash equivalents and restricted cash		19,673				37,035
Cash, cash equivalents and restricted cash at beginning of period		217,330				154,996
Cash, cash equivalents and restricted cash at end of period	$	237,003			$	192,031

CASH, CASH EQUIVALENTS AND RESTRICTED CASH
(Unaudited)
(In thousands)
	June 30,			December 31,
	2024			2023
Cash and cash equivalents	$	235,915		$	216,454
Restricted cash		1,088			876
Total cash, cash equivalents and restricted cash	$	237,003		$	217,330

VERACYTE, INC.
RECONCILIATION OF U.S. GAAP to NON-GAAP FINANCIAL MEASURES
(Unaudited)
(In thousands)
	Three Months Ended June 30,								Six Months Ended June 30,
	2024				2023				2024				2023
Reconciliation of Non-GAAP Gross Margin:
GAAP Gross Profit	$	77,913			$	55,820			$	140,381			$	107,209
GAAP Gross Margin		68	%			62	%			66	%			62	%
Amortization of intangible assets		2,909				4,814				5,824				9,618
Stock-based compensation expense		604				497				1,091				884
Acquisition related expenses (1)		—				—				60				74
Other adjustments (2)		—				—				6				—
Non-GAAP Gross Profit	$	81,426			$	61,131			$	147,362			$	117,785
Non-GAAP Gross Margin		71	%			68	%			70	%			68	%
Reconciliation of Non-GAAP Operating Expenses:
GAAP research and development	$	16,465			$	12,541			$	32,430			$	25,310
Stock-based compensation expense		(1,895	)			(1,439	)			(3,658	)			(2,696	)
Acquisition related expenses (1)		23				—				(397	)			—
Other adjustments (2)		2				—				(276	)			—
Non-GAAP research and development	$	14,595			$	11,102			$	28,099			$	22,614
GAAP sales and marketing	$	24,216			$	25,756			$	47,998			$	51,886
Stock-based compensation expense		(2,142	)			(2,494	)			(3,235	)			(4,606	)
Acquisition related expenses (1)		—				(567	)			(124	)			(1,158	)
Other adjustments (2)		(194	)			—				(1,094	)			—
Non-GAAP sales and marketing	$	21,880			$	22,695			$	43,545			$	46,122
GAAP general and administrative	$	31,745			$	25,047			$	57,955			$	46,100
Stock-based compensation expense		(5,213	)			(6,019	)			(9,889	)			(10,364	)
Acquisition related expenses (1)		(1,116	)			(1,134	)			(4,585	)			(1,624	)
Other adjustments (2)		(2,854	)			—				(3,120	)			66
Non-GAAP general and administrative	$	22,562			$	17,894			$	40,361			$	34,178
GAAP total operating expenses	$	73,307			$	63,871			$	140,431			$	125,758
Amortization of intangible assets		(881	)			(527	)			(1,619	)			(1,052	)
Stock-based compensation expense		(9,250	)			(9,952	)			(16,782	)			(17,666	)
Acquisition related expenses (1)		(1,093	)			(1,701	)			(5,536	)			(2,782	)
Other adjustments (2)		(3,046	)			—				(4,490	)			(1,344	)
Non-GAAP total operating expenses	$	59,037			$	51,691			$	112,004			$	102,914

1. Includes transaction-related expenses as well as post-combination compensation expenses. For the three months ended June 30, 2024, adjustments consist primarily of transaction related expenses associated with the acquisition of C2i Genomics ($1.0 million) and adjustments relating to the remeasurement of contingent consideration related to our adoption of a multi-platform IVD strategy ($0.1 million). For the three months ended June 30, 2023, adjustments consist primarily of post-combination compensation expenses associated with the acquisition of HalioDx. For the six months ended June 30, 2024, adjustments consist of transaction related expenses associated with the acquisition of C2i Genomics. For the six months ended June 30, 2023, adjustments consist primarily of post-combination compensation expenses associated with the acquisition of HalioDx.
2. For the three months ended June 30, 2024, adjustments primarily include expense related to restructuring costs associated with a reduction in our Biopharmaceutical and Other segment ($2.9 million) and expense related to restructuring costs associated with portfolio prioritization including the reduction in Envisia commercial support ($0.2 million). For the six months ended June 30, 2024, adjustments include additional restructuring costs associated with the portfolio prioritization including the reduction in Envisia commercial support ($1.4 million). For the six months ended June 30, 2023, includes $1.3 million related to impairment charges.

VERACYTE, INC.
RECONCILIATION OF U.S. GAAP to NON-GAAP FINANCIAL MEASURES
(Unaudited)
(In thousands)
	Three Months Ended June 30,								Six Months Ended June 30,
	2024				2023				2024				2023
Reconciliation of Adjusted EBITDA:
GAAP Net Income (Loss)	$	5,734			$	(8,402	)		$	3,870			$	(16,493	)
Amortization of intangible assets		3,790				5,341				7,443				10,670
Depreciation expense		1,948				1,518				3,885				2,859
Stock-based compensation expense		9,854				10,449				17,873				18,550
Acquisition related expenses (1)		1,093				1,701				5,596				2,856
Other expense (income), net (2)		(3,052	)			287				(6,313	)			(1,902	)
Other adjustments (3)		3,046				—				4,496				1,344
Income tax expense (benefit)		1,627				125				1,583				125
Adjusted EBITDA	$	24,040			$	11,019			$	38,433			$	18,009
Reconciliation of Non-GAAP Net Income (Loss)
GAAP Net Income (Loss)	$	5,734			$	(8,402	)		$	3,870			$	(16,493	)
Amortization of intangible assets		3,790				5,341				7,443				10,670
Stock-based compensation expense		9,854				10,449				17,873				18,550
Acquisition related expenses (1)		1,093				1,701				5,596				2,856
Other adjustments (3)		3,046				—				4,496				1,344
Tax adjustments (4)		(114	)			(551	)			(1,246	)			(1,127	)
Non-GAAP Net Income	$	23,403			$	8,538			$	38,032			$	15,800
Reconciliation of Non-GAAP Earnings per Share
Diluted earnings per share, GAAP	$	0.07			$	(0.12	)		$	0.05			$	(0.23	)
Amortization of intangible assets		0.05				0.07				0.10				0.15
Stock-based compensation expense		0.13				0.14				0.23				0.26
Acquisition related expenses (1)		0.01				0.02				0.07				0.04
Other adjustments (3)		0.04				—				0.06				0.02
Tax adjustments (4)		—				(0.01	)			(0.02	)			(0.02	)
Rounding and impact of dilutive shares		—				0.02				0.01				(0.01	)
Diluted earnings per share, non-GAAP	$	0.30			$	0.12			$	0.50			$	0.21
Weighted average shares outstanding used in computing diluted earnings per share
Diluted, GAAP		77,163,149				72,478,662				76,600,079				72,327,897
Dilutive effect of equity awards (5)		—				1,221,721				—				1,354,135
Diluted, non-GAAP		77,163,149				73,700,383				76,600,079				73,682,032

1. Includes transaction-related expenses as well as post-combination compensation expenses. For the three months ended June 30, 2024, adjustments consist primarily of transaction related expenses associated with the acquisition of C2i Genomics ($1.0 million) and adjustments relating to the remeasurement of contingent consideration related to our adoption of a multi-platform IVD strategy ($0.1 million). For the three months ended June 30, 2023, adjustments consist primarily of post-combination compensation expenses associated with the acquisition of HalioDx. For the six months ended June 30, 2024, adjustments consist of transaction related expenses associated with the acquisition of C2i Genomics. For the six months ended June 30, 2023, adjustments consist primarily of post-combination compensation expenses associated with the acquisition of HalioDx.
2. Includes interest income and income related to research tax credits.
3. For the three months ended June 30, 2024, adjustments primarily include expense related to restructuring costs associated with a reduction in our Biopharmaceutical and Other segment ($2.9 million) and expense related to restructuring costs associated with portfolio prioritization including the reduction in Envisia commercial support ($0.2 million). For the six months ended June 30, 2024, adjustments include additional restructuring costs associated with the portfolio prioritization including the reduction in Envisia commercial support ($1.4 million). For the six months ended June 30, 2023, includes $1.3 million related to impairment charges.
4. Incremental non-GAAP tax expense reflects the tax impact of the non-GAAP adjustments listed.
5. In those periods in which GAAP net (loss) income is negative and Non-GAAP net (loss) income is positive, Non-GAAP diluted weighted average shares outstanding includes potentially dilutive common shares from equity awards as determined using the treasury stock method.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20240806651491/en/

Investors:

Shayla Gorman

investors@veracyte.com

619-393-1545

Media:

Tracy Morris

media@veracyte.com

650-380-4413

Source: Veracyte, Inc.

FAQ

What was Veracyte's total revenue for Q2 2024?

Veracyte's total revenue for Q2 2024 was $114.4 million, an increase of 27% compared to Q2 2023.

How much did Veracyte's testing revenue grow in Q2 2024?

Veracyte's testing revenue grew by 31% in Q2 2024, reaching $107.0 million.

What was Veracyte's net income for Q2 2024?

Veracyte's net income for Q2 2024 was $5.7 million, an increase of 168% compared to Q2 2023.

What was Veracyte's adjusted EBITDA for Q2 2024?

Veracyte's adjusted EBITDA for Q2 2024 was $24.0 million, an improvement of 118% compared to Q2 2023.

What is Veracyte's updated revenue guidance for 2024?

Veracyte has updated its 2024 revenue guidance to $432-$438 million, representing year-over-year growth of 20% to 21%.